Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Subscribe To Our Newsletter & Stay Updated
